What are the investment strengths of Viking Therapeutics Inc (VKTX)?

Fortress balance sheet (713M equity, near-zero debt) provides 3+ years runway to reach clinical catalysts without dilution - rare for pre-revenue biotech R&D spend 5.7x industry median signals late-stage pipeline with potential near-term readouts that could justify 3.2B market cap

What are the investment risks for Viking Therapeutics Inc (VKTX)?

Binary risk: 3.2B valuation on zero revenue means 70%+ downside if lead programs fail - no revenue diversification buffer Burn rate of 225M/yr accelerating (opex 275M) - eventual dilution likely if trials extend or expand

Viking Therapeutics Inc

VKTX

—

Build a strategy around VKTX

Viking Therapeutics Inc AI Insights

Informational only. Not investment advice.

As of 2026-02-06

Snapshot

Zero revenue pre-commercial biotech burning 225M/yr FCF with 739M assets - ~3.3 years runway at current burn rate without dilution[Free Cash Flow TTM]
R&D spend of 222M TTM (81% of opex) vs industry median 39M - heavy clinical investment signals late-stage pipeline[Research and Development TTM]
Market cap 3.2B on zero revenue implies binary event pricing - P/B of 4.5x on 713M equity[Price to Book Ratio]

Watch Triggers

Cash and Equivalents: Falls below 400M — Sub-2yr runway triggers dilution risk; watch for ATM filings or PIPE deals
Research and Development TTM: Increases >30% YoY — Signals Phase 3 expansion or new programs - bullish but accelerates burn
Total Revenue TTM: Any revenue recognition — Partnership/licensing revenue would validate pipeline and extend runway

Bull Case

Fortress balance sheet (713M equity, near-zero debt) provides 3+ years runway to reach clinical catalysts without dilution - rare for pre-revenue biotech

Working CapitalDebt to EquityTotal Assets

R&D spend 5.7x industry median signals late-stage pipeline with potential near-term readouts that could justify 3.2B market cap

Research and Development TTMMarket Cap TTM

Bear Case

Binary risk: 3.2B valuation on zero revenue means 70%+ downside if lead programs fail - no revenue diversification buffer

Total Revenue TTMMarket Cap TTMEnterprise Value

Burn rate of 225M/yr accelerating (opex 275M) - eventual dilution likely if trials extend or expand

Free Cash Flow TTMOperating Expense TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

40%

Leverage VKTX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway extends to mid-2029 without dilution if burn stabilizes near current 225M/yr rate

1-3ymed

739M total assets, 100M cash + 638M likely in securities
Debt near zero (0.8M) eliminates refinancing risk
Investment sales of 181M TTM shows liquid portfolio

Working capital 713M vs 26M current liabilitiesDebt/equity 0.001 - essentially debt-freeNet investment sales 160M TTM

Valuation premium (4.5x book) prices in significant clinical success probability

1-3ylow

EV of 3.1B on pre-revenue company
R&D intensity 5.7x industry median suggests advanced programs
Zero dilution TTM preserves shareholder value

Market cap 3.2B vs tangible book 713MR&D 222M vs median 39MIssuance of capital stock: 0 TTM

Valuation Context

Caveats

VKTX Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	YoY Growth	Industry Percentile
Market Cap	$3.42B		—
Enterprise Value	$3.3B		—
P/E Ratio	0.00		—
Total Revenue - TTM	$0		—
Earnings Per Share (diluted) - TTM	$-4.15		—
Operating Margin - TTM	0%		—
Net Margin - TTM	0%		—
Free Cash Flow - TTM	$-340.33M		—
Return on Common Equity - TTM	-70.0%	-55.6%	—
Beta 5Y (Monthly)	unknown		—

VKTX Dividend History

No dividends

VKTX Stock Splits

No stock splits

VKTX SEC Filings

Filing Date	Report Date	Report Type	Filing Link
04/30/26	03/31/26	10-Q	0001193125-26-193315
02/11/26	12/31/25	10-K	0001193125-26-046876
10/23/25	09/30/25	10-Q	0001193125-25-247059
07/23/25	06/30/25	10-Q	0000950170-25-097950
04/24/25	03/31/25	10-Q	0000950170-25-058129
02/26/25	12/31/24	Unknown	0000950170-25-027824
10/23/24	09/30/24	10-Q	0000950170-24-116708
07/24/24	06/30/24	10-Q	0000950170-24-086111
04/25/24	03/31/24	10-Q	0000950170-24-047833
02/07/24	12/31/23	10-K	0000950170-24-012322
10/25/23	09/30/23	10-Q	0000950170-23-055259
07/26/23	06/30/23	10-Q	0000950170-23-034773
04/26/23	03/31/23	10-Q	0000950170-23-014883
02/10/23	12/31/22	10-K	0001564590-23-001685
10/26/22	09/30/22	10-Q	0001564590-22-035295
07/27/22	06/30/22	10-Q	0001564590-22-026717
04/27/22	03/31/22	10-Q	0001564590-22-016129
02/09/22	12/31/21	10-K	0001564590-22-004429
11/03/21	09/30/21	10-Q	0001564590-21-054030
07/28/21	06/30/21	10-Q	0001564590-21-038663
04/28/21	03/31/21	10-Q	0001564590-21-021430
02/17/21	12/31/20	10-K	0001564590-21-006406
10/28/20	09/30/20	10-Q	0001564590-20-048398
07/29/20	06/30/20	10-Q	0001564590-20-034329
04/30/20	03/31/20	10-Q	0001564590-20-020233
02/26/20	12/31/19	10-K	0001564590-20-006766
11/05/19	09/30/19	10-Q	0001564590-19-040424
08/01/19	06/30/19	10-Q	0001564590-19-028043
05/02/19	03/31/19	10-Q	0001564590-19-015390
03/13/19	12/31/18	10-K	0001564590-19-007584
11/07/18	09/30/18	10-Q	0001564590-18-028101
08/09/18	06/30/18	10-Q	0001564590-18-021125
05/09/18	03/31/18	10-Q	0001564590-18-012501
03/07/18	12/31/17	10-K	0001564590-18-004757
11/08/17	09/30/17	10-Q	0001564590-17-022829
08/09/17	06/30/17	10-Q	0001564590-17-017021
05/10/17	03/31/17	10-Q	0001564590-17-010332
03/21/17	12/31/16	10-K	0001564590-17-004911
11/10/16	09/30/16	10-Q	0001564590-16-028979
08/11/16	06/30/16	10-Q	0001564590-16-024067
05/10/16	03/31/16	10-Q	0001564590-16-018987
03/08/16	12/31/15	10-K	0001564590-16-014212
11/05/15	09/30/15	10-Q	0001564590-15-009694
08/14/15	06/30/15	10-Q	0001193125-15-291529
06/12/15	03/31/15	10-Q	0001193125-15-220837
04/29/15	12/31/14	424B4	0001193125-15-156831
11/05/15	09/30/14	10-Q	0001564590-15-009694
09/02/14	06/30/14	S-1/A	0001193125-14-329131
07/01/14	03/31/14	S-1	0001193125-14-257855
09/02/14	06/30/13	S-1/A	0001193125-14-329131
07/01/14	03/31/13	S-1	0001193125-14-257855
07/01/14	12/31/12	S-1	0001193125-14-257855